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Abstract: Adult T-cell leukemia/lymphoma (ATLL) is a distinct disease 
caused by the first discovered human oncogenic retrovirus, human T-cell 
leukemia virus type-1 (HTLV-1).  The peculiarity of this disease is not only 
in its causative agent HTLV-1 but also in the character of leukemia cells.  
ATLL cells express the mature helper/inducer T-cell antigens, CD2, CD3, 
CD4 and CD5 but usually lacking CD8.  Despite of CD4 expression, it has 
long been known that ATLL cells exhibit strong immunosuppressive activity 
in vitro.  Notably, ATLL patients are in severely immunosuppressed 
conditions and this causes higher incidences of opportunistic infections than 
other types of leukemia and lymphoma.  Since ATLL cells constitutively 
express CD25, this prompted investigators to study ATLL cells from the 
viewpoint of regulatory T cells (Treg cells).  ATLL cells satisfy all the 
criteria of Treg cells, as they express Foxp3, the master gene of Treg lineage, 
the glucocorticoid-induced TNF receptor (GITR), and the cytotoxic 
T-lymphocyte associated molecul-4 (CTLA-4).  Moreover, other profiles 
including chemokine receptor expression also support that ATLL is a 
neoplasm of Treg cell origin.  Here we review the immunological aspects of 




   ATLL was proposed as a new disease entity in 1977 because of its limited 
distribution of the patients’ birthplaces in the Kyushu area of Japan and 
more suggestively its peculiar clinical and laboratory findings [1].  
Hypercalcemia and involvement of the skin and visceral organs, especially 
that of the lung, liver, and gastro-intestinal tracts, are frequent signs of the 
disease, and ATLL cells show a characteristic morphology with 
multi-lobulated nuclei called flower cells (Fig. 1).   In 1981, its causative 
agent HTLV-1 was discovered [2-3], and the geographic clustering of the 
HTLV-1 carriers and HTLV-1-related diseases was recognized: Japanese in 
Asia, Melanesians in near Oceania, blacks in central Africa and the 
Caribbean basin, and American Indians in Central and South America [4].  
The regional clustering is explained by mother-to-child transmission of the 
virus by breast-feeding in closed communities [5,6].  Although ATLL is an 
all encompassing term that is designed to highlight monoclonal nature of the 
disease and define it as a condition that involves the monoclonal 
proliferation of HTLV-1-infected T-lymphocytes (Fig. 2), its clinical behavior 
is quite diverse among patients.  ATLL is thus subclassified into four 
subtypes; the smoldering and chronic types are indolent subtypes and the 
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acute and lymphoma types are aggressive subtypes [7].  Patients with the 
indolent subtypes survive several years even without chemotherapy, but the 
prognosis of the aggressive subtypes is extremely poor and their median 
survival time is only 13 months even in the recent multicenter clinical trial 
performed in Japan [8].   
   One of the causes of poor prognosis comes from suppression of their 
immunosurveillance system, and the patients with aggressive subtypes are 
sometimes found with opportunistic infections such as Pneumocystis jiroveci 
pneumonia, fungal infection, or Cytomegalovirus infection before and/or 
during treatment (Table 1) [9], which makes it difficult to start or continue 
chemotherapy.  Moreover, some patients show conditions similar to 
hyper-IgE syndrome that is characterized by recurrent staphylococcal 
infections of the skin, chronic eczema-like rashes, eosinophilia, and 
markedly elevated serum IgE levels [10,11].  Another piece of evidence for 
the immunosuppression that occurs in ATLL is the low response to the 
tuberculin skin test that is used to assess the general status of individual 
cellular immunity in Japan.  Since the BCG vaccination is given to all 
individuals who show a negative reaction to the test, 70 to 80% of Japanese 
around 60 years of age, the median age of ATLL patients, show a positive 
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reaction.  The prevalence of positivity for the tuberculin skin test in acute 
type and lymphoma type ATLL patients is very low (15% and 25%, 
respectively), which is significantly different from its prevalence in other 
lymphoproliferative disorders (p<0.05) [12].  Notably, tuberculin skin 
test-negative patients produce a positive reaction after they have achieved 
complete remission [12], suggesting that ATLL cells play an 
immunosuppressive activity in vivo.  
 
The immunological characteristics of ATLL cells  
   1. T cell-related markers (Table 2) 
   ATLL cells display an activated mature helper/inducer T-cell phenotype: 
CD1-, CD2+, CD3+, CD4+, CD5+, CD7-, CD8-, and HLA-DR+ (Fig. 3) [13].  
T-cell receptors (TCR) are always α/β heterodimers and no patients with γ/δ 
heterodimers have been reported.   The density of cell surface CD3/TCR 
molecules is usually low compared with normal T cells or other mature T-cell 
malignancies despite their high mRNA expression, and this discordance is 
also believed to be one of the characteristics of ATLL cells [14, 15].  
Although more than 80% cases show the CD4+CD8- phenotype, some cases 
show a double positive (CD4+CD8+), double negative (CD4-CD8-), or even 
 5
CD8+ single positive phenotype [16, 17].  Loss of CD2 and/or CD5 antigens 
is also not rare, and the prognosis of these aberrant cases is usually poor [16].  
Moreover, ATLL cells sometimes change surface phenotype to aberrant forms, 
gain CD8 or lose CD4, at relapse or at the exacerbation phase [18, 19]. 
   Mature T cells are divided into two categories according to their antigen 
stimulation, naïve T cells before stimulation and memory T cells after 
stimulation, which are distinguished by the two isoforms of leukocyte 
common antigen family (LCA, CD45); naïve T cells are CD45RA+ and 
memory T cells are CD45RO+.  ATLL cells are usually CD45RA-CD45RO+ 
with a few exceptional cases being CD45RA+CD45RO+ double positive [19].  
Consistent CD45RO expression interpreted as indicating that the target 
cells for HTLV-I-induced neoplastic transformation are helper memory T 
cells.  Alternatively, this may simply reflect the activated T cell nature of 
ATLL cells because it has been reported that CD45RO expression is induced 
following T-cell activation [20]. 
   ATLL cells express CD30 [21, 22], a member of the TNF receptor 
superfamily known to be expressed on activated T and B cells, and this 
result also supports the idea that ATLL cells are in an activated phase.  
Elevated CD30 expression is considered one of the causes of the constitutive 
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NF-κB activation observed in ATLL cells, which is believed to be involved in 
ATLL oncogenesis [22, 23].  Another T cell activation marker, CD44, is also 
expressed in ATLL cells [24].  In contrast, although CD26/dipeptidyl 
peptidase IV is also known to be upregulated during T cell activation, ATLL 
cells either lack it or profoundly down-regulate its expression [25, 26].  The 
pathological significance of this down-regulation has not been elucidated. 
   2. Cytokines and cytokine receptors (Table 2) 
   Helper T cells are divided into two subsets, T helper 1 (Th1) and T helper 
2 (Th2), according to their cytokine production patterns [27].  Th1 cells 
produce interleukin 2 (IL-2), interferon γ (IFN-γ), and tumor necrosis factor β 
(TNF-β) and are involved in cell-mediated inflammatory reactions, i.e. Th1 
cells induce delayed-type hypersensitivity (DTH).  In contrast, Th2 cells 
produce IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13 and are involved in humoral 
immune responses, i.e. Th2 cells help antibody production, particularly IgE 
responses.  The production of IL-2, IL-6, IL-10, and IL-13 is, however, not 
tightly restricted between the two subsets in humans as is the case in 
murine T cells, moreover, both subsets produce IL-3, TNF-α, and 
granulocyte-macrophage colony-stimulating factor (GM-CSF) [27].  There 
are other two subsets, Th0 and Th3; Th0 produce both Th1 and Th2 cell 
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cytokines, and Th3 produces IL-10 and transforming growth factor-β (TGF-β).  
These overlapping characteristics make it difficult to determine which 
objective T cells belong to which subset.  In a practical and simplified 
setting, it may be possible to say that Th1 cells are characterized by 
producing IFN-γ and that Th2 cells are characterized by producing IL-4.  
Since ATLL cells show a characteristic cell surface phenotype, ATLL is 
believed to be derived from a distinct helper T cell subset, and hence ATLL 
cells may show a restricted cytokine production pattern.  In the analysis of 
ATLL cell lines as pure ATLL cell samples, ATLL cell lines from different 
patients indeed showed the same cytokine producing profile, namely, they 
produced IFN-γ, IL-6, IL-8, LD78/MIP-1α, TNF-α, M-CSF, and GM-CSF but 
did not produce IL-1α, IL-1β, IL-2, IL-4, IFN-α, or G-CSF [28, 29].  The 
positive production of IFN-γ and the negative production of IL-4 suggest that 
ATLL cells are of Th1 subset origin.  This interpretation, however, faces the 
difficulty that HTLV-1 Tax protein influences for cellular genes including 
those cytokines.  HTLV-I possesses a unique 3’ region in its genome, 
designated as pX, which encodes the viral transactivator Tax protein.  Tax 
transactivates not only its own gene expression but also many kind cellular 
genes such as IL-1α, -1β, -2, -3, -4, -5, -6, -8, -10, -15, GM-CSF, G-CSF, TNF-α, 
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TNF-β, IFN-γ, LD78/MIP-1α, MIP-1β and MCP-1, PDGF, TGF-β, NGF, and 
PTHrP [30, 31].  Accordingly, the unexpected production of IL-6 in ATLL 
cells may be attributable to the Tax protein, or alternatively, the 
Th1-Th2-dichotomy may not be fitting to determine neoplastic cell origins.  
Th17, another newly described lineage of CD4 T cells, is characterized by the 
production of IL-17, IL-17F, and IL-6 [32].  Although it has been 
demonstrated that the skewing of helper T cells toward either Th17 cells or 
Treg cells is mutually exclusive in murine systems [32, 33], there is no such 
evidence in humans [34].  It has been reported that Tax protein induces 
IL-17 gene expression in T cells [35], but IL-17 production in primary ATLL 
cells has not yet been examined. 
   In contrast to such ambiguous cytokine production, ATLL cells show a 
distinct cytokine receptor expression profile.  One of the most characteristic 
features is the expression of the IL-2 receptor (IL-2R) αchain (CD25) [36].  
IL-2R consists of three components, the α-chain, β-chain, and γ-chain.  
IL-2R γ-chain is called common γ (γc), and the receptors that share γc are 
called the γc-receptor family; IL-4R, IL-7R, IL-9R, IL-15R, and IL-21R belong 
to this family.  Interestingly, ATLL cells express all these members except 
IL-9R, and more importantly, these receptors are functional and IL-2, IL-4, 
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IL-7, IL-15, and IL-21 stimulate the proliferation of primary ATLL cells 
[36-39], suggesting their pathological roles.  Among them, IL-15 is unique 
in the sense that its mRNA and/or protein are detected in a variety of human 
cells and tissues, such as monocytes, macrophages, dendritic cells, the skin, 
the liver, the kidneys, and the lungs etc, although other cytokines are 
entirely produced from T cells in the immune system.  The frequent 
invasion and rapid proliferation of ATLL cells in a variety of tissues and 
organs may thus be attributable to local IL-15 production [40].  HTLV-1 Tax 
protein transactivates the genes for IL-2Rα and IL-15Rα [31, 41, 42], whose 
function may be related to the deregulated expression of these receptors in 
ATLL. 
   3. Chemokines and chemokine receptors (Table 2) 
   Chemokines induce the directed migration of target cells by interaction 
with chemokine receptors that have seven transmembrane domains coupled 
to a G-protein [43-45].  The differential expression of chemokine receptors 
on lymphocytes correlates with their tissue-specific homing and immune 
functions.  It has been reported that Th1 and Th2 cells differentially 
express chemokine receptors; Th1 cells preferentially express CXCR3 and 
CCR5, whereas Th2 cells express CCR4, and to a lesser extent, CCR3 [46].  
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Since primary ATLL cells express CCR1, CCR4, CCR7, CCR8, CCR10, and 
CXCR4 but hardly express CCR2, CCR3, CCR5, CCR6, CXCR1, CXCR2, 
CXCR3, or CXCR5 [47-49], ATLL cells fit, if anything, Th2 cell character.  
This, however, does not agree with the hypothesis obtained by the cytokine 
production profile that indicated Th1 cell origin.  Again, it may not be 
appropriate to apply the Th1-Th2-dichotomy to the origin of lymphoid 
neoplasms, or the Th1-Th2-dichotomy may not correlate with chemokine 
receptor expression in humans as it has been reported that chemokine 
receptors are not significantly different between Th1 and Th2 cells in normal 
human peripheral blood [50]. 
   Although the Th1-Th2-dichotomy is thus unclear in ATLL cells, the 
expressed chemokine receptors are functional and do correlate with clinical 
manifestations.  CCR7 is necessary for the homing of naïve and memory T 
cells to secondary lymphoid organs through the gateway of high endothelial 
venules [51].  ATLL cells express CCR7, and migrate toward CCR7 
chemokines, CCL19 (EBI1-ligand chemokine: ELC), and CCL21 (secondary 
lymphoid-tissue chemokine: SLC) [47].  Consequently, ATLL cells from 
patients with lymphoid organ involvement express significantly higher levels 
of CCR7 than control CD4+CD45RO+ T cells or ATLL cells from patients 
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without lymphoid organ involvement [47].  CCR4 is selectively expressed by 
cutaneous lymphocyte-associated antigen (CLA)-positive skin-homing 
memory T cells.  ATLL cells from almost all patients express CCR4 and 
show vigorous migration toward its ligands, CCL17 (thymus and 
activation-regulated chemokine: TARC), and CCL22 (macrophage-derived 
chemokine: MDC) that are produced from epidermal keratinocytes [48].  
Moreover, ATLL skin lesions contain abundant transcripts of CCR4, CCL17, 
and CCL22, indicating a significant role for CCR4 expression in skin 
invasion.  Another skin-homing chemokine receptor CCR10, which is 
expressed in a fraction of CLA+ T cells [52, 53], is also expressed in ATLL 
cells, and ATLL cells migrate toward its ligand, CCL27 (cutaneous T-cell 
attracting chemokine: CTACK) [49].  These results indicate that ATLL cells 
have a high affinity for the skin.  In fact, a variety of skin lesions, erythema, 
papules, and nodule- or tumor-formations are observed in more than one 
third of ATLL patients from the first diagnosis.  Another unique 
characteristic is that ATLL cells not only express CCR8 but also produce its 
ligand CCL1 (I-309) [54].  Since CCL1 inhibits the apoptosis of ATLL cells, 
an anti-apoptotic autocrine mechanism is suggested [54]. 
   4. Other cell surface markers (Table 2) 
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   Fas (APO-1/CD95) is a member of the tumor necrosis factor (TNF)/nerve 
growth factor (NGF) receptor superfamily.  Cross-linking of cell membrane 
Fas (mFas) by Fas ligand (FasL) or by agonistic IgM anti-Fas monoclonal 
antibodies transduces a death signal, producing apoptosis [55].  Primary 
ATLL cells express mFas [56], which is a characteristic of activated 
CD45RO+ T-cells.  In spite of its expression, ATLL cells are usually 
resistant to Fas-medicated apoptosis [57].  Since the Fas ligand is produced 
daily as a result of immune reactions, ATLL cells should have been exposed 
to the FasL in vivo.  ATLL cells have protection mechanisms against FasL.  
One of these mechanisms is the production of soluble Fas (sFas), which lacks 
a transmembrane domain and captures and inactivates FasL.  ATLL cells 
secrete sFas, and the sera from ATLL patients contain significantly higher 
concentrations of sFas than sera from healthy adults [58, 59].  Another 
mechanism is a function ablating Fas gene mutation that loses the ability to 
transduce the death signal, and ATLL patients with such mutations have 
been reported [60, 61].  In addition, HTLV-1 Tax protein confers resistant 
mechanisms on ATLL cells at multiple levels towards the apoptosis cascade 
[62]. 
   TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in 
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many transformed cells, but not in normal cells, and hence, TRAIL has 
recently emerged as a novel anti-cancer agent.  Although primary ATLL 
cells express the TRAIL-death receptors, DR4 and DR5, they are usually 
resistant to TRAIL exposure [63].  The resistance mechanism is complex 
and is not explained by a single factor, but HTLV-1 Tax, at least in part, 
seems to be involved in this mechanism [63]. 
 
Regulatory T cells (Treg cells) 
   More than 30 years ago, two groups proposed the concept of suppressor T 
cells [64-66].  They aimed to disclose the suppression mechanism and 
asserted that the activity was mediated by antigen-specific suppressor cells.  
They, however, ceased this assertion by the middle of 1980s and stopped 
using the term “suppressor T cells”, mostly because they had failed to clone 
suppressor factors and to identify the responsible gene I-J locus [67-70].  In 
a different stream of immune suppression study, Nishizuka and Sakakura 
showed that neonatal thymectomy in normal mice resulted in the 
development of an autoimmune disease [71].  Later, Sakaguchi et al. 
showed that depletion of Lyt-1 (CD5) cells from adult mice resulted in the 
development of autoimmune diseases, whereas depletion of Lyt-2 (CD8) cells 
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did not, suggesting the existence of suppressor T cells in the CD5+CD8- cell 
population [72].  They, thereafter, confirmed that the suppressor cells 
(currently termed Treg cells) existed in the CD4+ T cell fraction [73].  
Interestingly, the suppressor activity was mediated by CD4+ T cells 
characterized by CD25 expression; when CD4+ cell suspensions were 
depleted of CD25+ cells and then inoculated into BALB/c athymic nude 
(nu/nu) mice, all recipients spontaneously developed several kinds of 
autoimmune diseases [73].  The reconstitution of CD4+CD25+ cells within a 
limited period after the transfer of CD4+CD25- cells prevented the 
development in a dose dependent manner.  Of note, the depletion of 
CD4+CD25+ T cells enhanced immune responses not only against 
self-antigens but also against non-self antigens including soluble xenogeneic 
proteins and allografts.  They therefore concluded that CD4+CD25+ cells 
contribute to maintaining self-tolerance by down-regulating the immune 
response to self and non-self antigens in an antigen-nonspecific manner, 
presumably at the T cell activation stage.  The suppressive activity of 
CD4+CD25+ cells has also been confirmed in vitro, and CD4+CD25+ cells 
suppressed the proliferation of anti-CD3- and concanavalin A 
(ConA)-induced CD4+CD25- T cells proliferation, the mechanism of which 
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was dependent on the manner of cell-to-cell contact and did not require 
soluble factors [74, 75]. 
   In 2001, Foxp3, a member of the forkhead/winged-helix family of 
transcriptional regulators, was identified to be the causative gene of scurfy 
mice that are characterized by overproliferation of CD4+CD8- T cells, 
extensive multiorgan infiltration, and the elevation of numerous cytokines 
such as IL-4, IL-6, IL-7, and TNF-α [76, 77].  IPEX (immune dysregulation, 
polyendocrinopathy, enteropathy, and X-linked syndrome) is a human 
counterpart of scurfy mice and is caused by different mutations of Foxp3 [78].  
Foxp3 is specifically expressed in naturally arising Treg cells in mice, 
furthermore, retroviral gene transfer of Foxp3 converts naïve T cells toward 
a Treg phenotype similar to that of naturally occurring Treg cells, indicating 
that Foxp3 is the master controller of Treg cell development and function 
[79].  There are, however, some differences between mouse and human 
Foxp3, and it has been reported that human CD4+ T cells with ectopically 
overexpressed Foxp3 do not acquire significant suppressor activity in vitro 
[80].  Moreover, Foxp3 mRNA expression could be induced not only in 
CD4+CD25- but also in CD8+ peripheral blood T cells in humans by cell 
activation [81].  Conversely, IL-10-producing regulatory T cells (Tr1) do not 
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constitutively express Foxp3 although they do exhibit suppressive activity 
[82].  Thus, Foxp3 is a poor marker of regulatory T cells in humans.   
   Several other molecules are also known to be associated with Treg cell 
function.  Treg cells express CTLA-4 that is essential in T cell-mediated 
dominant immunologic self-tolerance [83, 84], and in vivo blockade of 
CTLA-4 in normal mice leads to the spontaneous development of 
autoimmune diseases.  Treg cells express high and persistent levels of 
TGF-β on their cell surface, which is also essential for their functioning via 
cell-to-cell contact [85].  Anti-TGF-β antibody not only abrogates the 
suppression of CD4+CD25- T cell proliferation but also the suppression of B 
cell differentiation and immunoglobulin production by Treg cells.  GITR, a 
member of the tumor necrosis factor-nerve growth factor receptor family, is 
expressed on Treg cells, and the removal of GITR-expressing T cells produces 
organ-specific autoimmune disease in mice [86].  OX40 (CD134) and 4-1BB 
(CD137) are also expressed in Treg cells.  However, the specificity of these 
markers in Treg cells is controversial because they are up-regulated in 
non-Treg cells following activation.  As for chemokine receptor expression, it 
has been reported that human Treg cells display a restricted expression 
profile, namely CCR4+ and CCR8+, and CCR8 expression is more restricted 
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to Treg cells [87, 88].  The expression of CCR5, CCR6, and CCR7 in Treg 
cells has also been shown in murine systems.  Nowadays, there is a large 
body of evidence concerning the implications of Tregs in many immune 
processes such as tumor evasion, autoimmunity, and pathogen elimination.  
There are also numerous clinical trials being conducted in many parts of the 
world with the aim of using these cells as therapeutic agents. 
 
ATLL as a regulatory T-cell tumor 
   For a long time, the focus of the intensive research into T cell function has 
been the regulation of B cell differentiation, and this research was 
profoundly facilitated by the development of monoclonal antibodies against T 
cell subsets.  It was commonly accepted that the CD4+ T cell subset 
possessed helper activity and the CD8+ T cell subset possessed suppressive 
activity, and that CD4+ T cells served to induce the suppressive activity of 
CD8+ T cells [89, 90].  In 1978, Uchiyama et al. showed for the first time 
that primary ATLL cells exhibited a strong suppressive activity on pokeweed 
mitogen (PWM)-induced normal B-cell differentiation [91].  Other 
investigators also confirmed the activity, but the interpretation of the 
mechanism was conflicting among investigators; some asserted that ATLL 
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cells induced the suppressive activity of CD8+ T cells, but others asserted 
that ATLL cells directly acted as suppressors [92-95].  Since primary ATLL 
cells exhibit suppressive activity without the participation of normal CD8+ T 
cells, moreover, the effect is lost by radiation of ATLL cells but not of normal 
CD8+ cells [94, 95], it seems natural to think that ATLL cells themselves 
exhibit suppressive activity.  Importantly, the activity was mediated in a 
cell-to-cell contact-dependent manner, similar to the activity of Treg cells, 
and the supernatant of the ATLL cell culture did not contain suppressive 
activity [95].  The production of IL-10 and TGF-β from ATLL cells, the two 
major cytokines reported to be involved in Treg cell function, was disclosed 
later [96, 97]. 
   After the discovery of the Foxp3 gene in 2003 [79], many investigators 
reexamined ATLL cells from the viewpoint of Treg cells [98-103].  These 
studies revealed that ATLL cells indeed expressed Foxp3 although the 
expression level differed greatly among patients.  In the 
immunohistochemical analysis of 172 paraffin-embedded lymphoma samples, 
Foxp3 expression was confined to the ATLL cases, and no other lymphoma 
types exhibited Foxp3 expression [100].  ATLL cells also express other 
Treg-cell markers.  ATLL cells express significantly higher levels of GITR 
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mRNA than normal T cells, and HTLV-1 transactivator Tax induces GITR 
expression [99].  Since Tax, in contrast, does not transactivate the Foxp3 
gene [99], Foxp3 expression is undoubtedly an innate characteristic of ATLL 
cells.  ATLL cells express CTLA-4 and the expression correlates with Foxp3 
mRNA levels [102].  The expression of OX40 in ATLL cells was shown long 
time ago, and was interpreted to be involved in leukemic cell infiltration 
[104].  In recent functional analyses of ATLL cells, it was confirmed that 
ATLL cells inhibit Concanavalin A- and anti CD3 antibody-stimulated T cell 
proliferation in a dose dependent manner not only in an allogeneic setting 
but also in autologous setting [99, 101-103].  The activities were not 
abrogated by antibodies against TGF-β or IL-10, which excludes the 
participation of these molecules in the suppression mechanism [101].  The 
lack of IL-2 production is also one of the key markers for Treg cells [73, 74], 
and primary ATLL cells and ATLL cell lines never produce IL-2 after any 
stimulation including Ca-ionophore A23187 with ionomycin, 
phorbolmyristate acetate (PMA), and Con A [28, 102].   
   Since the retroviral transfection of Foxp3 does not confer any suppressive 
function on low Foxp3-expressing HTLV-1-infected cell lines, it is assumed 
that Foxp3 is essential but is not sufficient for Treg-cell-like suppressive 
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activity [101].  In other words, the suppressive activity of ATLL cells comes 
from their innate characteristics but not from Foxp3 expression.  In this 
aspect, it is interesting that, besides ATLL and HTLV-1-infected cell lines, 
Foxp3 mRNA was also detected in many kinds of human leukemia and 
transformed cell lines, although Foxp3 protein expression was limited in 
ATLL cell lines [105].  Moreover, a variety of primary human cancer cells 
also express Foxp3 [106, 107].  It is thus still debated at least in humans 
whether Foxp3 is an exclusive marker for Treg cells.  Recent publications 
have disclosed the novel role of Foxp3.  Foxp3 is expressed in mammalian 
epithelial cells and acts as a transcriptional repressor of oncogenes such as 
SKP2 and HER-2/ErbB2 [108, 109].  Deletion, functionally significant 
somatic mutations, and downregulation of the Foxp3 gene are commonly 
found in human breast cancer samples and correlate significantly with 
HER-2/ErbB2 overexpression [108].  
   Another difficulty for identifying Treg cells is that the molecule(s) 
responsible for the direct suppressive activity remains largely unknown.  It 
has recently been reported that Epstein-Barr-virus-induced gene 3 (Ebi3, 
which encodes IL-27β) and IL-12α (IL-12α, which encodes IL-12α/p35) are 
highly expressed by mouse Foxp3+ Treg cells but not by resting or activated 
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effector CD4+ T cells (Teff), and that an Ebi3-IL-12α heterodimer is 
constitutively secreted by Treg cells but not Teff cells [110].  This novel 
Ebi3-IL-12α heterodimeric cytokine has been designated IL-35 [111], and the 
ectopic expression of IL-35 confers regulatory activity on naïve T cells, 
moreover, recombinant IL-35 suppresses CD4+CD25- Teff cell proliferation 
[107, 110].  IL-35 also shows the activity in an in vivo setting, and 
attenuated established collagen-induced arthritis in mice [110].  These data 
identify IL-35 as a novel inhibitory cytokine that may be specifically 
produced by Treg cells.  There is, however, no available data about IL-35 
expression in human cells including ATLL cells.   
 
Conclusion 
   ATLL cells satisfy almost all the criteria for natural Treg cells; ATLL cells 
are CD4+CD25+, express Foxp3, CTLA-4, GITR, OX40, CCR4, and CCR8, 
and produce IL-10 and TGFβ, but not IL-2.  Furthermore, immunobiological 
analysis of ATLL cells in vitro and the in vivo profile of ATLL patients both 
support the assertion that ATLL is a neoplasm of Treg cells.  So, we wonder 
what we need to do next to confirm this theory.  Perhaps an examination of 
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Fig. 1. Peripheral blood ATLL cells. Typical ATLL cells with multi-lobulated 
nuclei, so called flower cells, are shown.   
 
Fig. 2. Southern blot analysis of HTLV-1 proviral DNA in primary leukemia 
samples.  Cellular DNA was digested with EcoR1 (E) or Pst1 (P), and 
hybridized with an HTLV-1 probe.  Since HTLV-1 does not have an EcoR1 
site but does have Pst1 sites, the presence of band(s) in EcoR1-digested DNA 
indicate the monoclonal proliferation of HTLV-1 integrated cells (ATLL 1 and 
ATLL 2).  In Pst1-digested DNA, in contrast, three internal bands of 2.4bp, 
1.6bp and 1.1bp (arrow heads) in length are observed even without the 
presence of monoclonal proliferation, if HTLV-1 infected cells are more than 
5%.  The presence of band(s) other than these three bands indicates the 
presence of monoclonal proliferation, and the loss of these bands indicates 
that the provirus is a defective virus.  M: size marker.  CL: positive control 
bands obtained by an ATLL cell line. 
 
Fig. 3. Surface phenotype of ATLL cells.  ATLL cells are CD2+, CD3+, CD4+, 
 40
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CD5+, CD7-, CD8- and express all members of the γc-receptor family except 
for IL-9R (IL-4R+, IL-7R+, IL-15R+, and IL-21R+). 
 
Fig. 4. Foxp3 and GITR expression in ATLL cells.  Quantitative analyses by 
real-time RT-PCR show a significant elevation of Foxp3 and GITR mRNAs in 





Table 1. Episodes of documented infections during admission (modified from Ref. no. [9]) 
                                            
 ATLL (n=112) NHL (n=109) p 
Bacterial pneumonia        23 (5)        10 (2) < 0.05 
Sepsis         6 (1)         3  
Skin infections         4 (1)         0 < 0.05 
Tuberculosis          3 (3)         0  
Pneumocystis jiroveci pneumonia         5 (3)         0 < 0.05 
Fungal infections        16 (1)         5 < 0.05 
Cytomegalovirus infection         9         1 < 0.05 
Herpes zoster        12 (2)         6  
Herpes simplex virus infection         9         0 < 0.01 
( ): number of infectious episodes before chemotherapy 
NHL: non-Hodgkin lymphoma 
Table 2. Immunological characteristics of ATLL cells 
 
T cell-related markers 
   Positive 
   Negative or very low 
 
CD2, CD3, CD4, CD5, CD30, CD45RO, TCRα/β 
CD1, CD7, CD26, CD45RA, TCRγ/δ 
(some cases show CD2-, CD5-, CD4+CD8+, CD4-CD8-, 
CD4-CD8+ and/or CD45RA+ phenotypes) 
Cytokine production 
   Positive 
 
   Negative 
 
IFNγ, IL-6, IL-8, LD78/MIP-1α, TNF-α, M-CSF, 
GM-CSF, VEGF 
IL-1α, IL-1β, IL-2, IL-4, IFNα, G-CSF 
Cytokine receptors 
   Positive 
 
IL-2Rα(CD25), IL-2Rβ, IL-2Rγ, IL-4R, IL-7R, IL-15R, 
IL-21R 
Chemokine receptors 
   Positive 
   Negative 
 
CCR1, CCR4, CCR7, CCR8, CCR10, CXCR4 




Table 3. Comparison of human Treg cells and ATLL cells 
 
 Human Treg cells ATLL cells 
Cell surface markers CD4+, CD8-, CD45RO+ CD4+, CD8-, CD45RO+ 
Cytokine production 
   Positive 




















   Positive 
 
Foxp3, GITR, CTLA-4, OX40 
 
Foxp3, GITR, CTLA-4, OX40 
Function 
   in vitro 
 
 
   in vivo 
 
Suppress CD4+CD25- T cell 
proliferation 
 
Develop autoimmune diseases  
if absent 
 
Suppress T cell proliferation and 
B cell differentiation 
 
Patients are in a severely 
immune suppressed condition 
 
 
 
